Development of novel protein drugs, antibodies and industrial proteins by directed Molecular Evolution technology.
Natural enzymes and antibodies often need to be optimized in order to be used in an industrial process or as a candidate product for diagnostics or therapeutics.
Invented and patented (WO 02/387566) by MilleGen, MutaGen™, associated to a HTS platform (MutaScreen) and a computer modelling platform (MAP), is currently the only available molecular evolution technology on the market able to create the largest libraries, controllable diversity and in the shortest delays.
This method constitutes an extremely efficient tool for optimising biomolecules. MilleGen possesses a high expertise in the MutaGen™ process, from design to production, applied to any DNA sequence coding for a biological function.
Through MutaGen™ technology, MilleGen aims to be a leading company in the designing of:
Antibody engineering: Antibody discovery platformAntibody generation (from our human libraries, against customer target) – Antibody improvement (for human, humanized and rodent antibodies, for therapeutic and diagnostic use), including humanisation and immunogenicity profiling.
Pharmaceutical proteins (new therapeutic targets) developed with pharmaceuticals and biotechnology partners,
Enzymes for the biocatalyst and agro-chemical industries.
MilleGen uses its proprietary MutaGen™ molecular evolution technology to generate large libraries of randomly mutated genes with a control of genetic diversity. Based on an in vitro replication with « mutases », MutaGen™ technology provides a powerful and simple approach to carrying out in vitro protein optimisation.
Millegen's expertise in screening processes and a robotic platform allows a fast high throughput screening of the mutants generated by the Mutagen™ system. The platform is adaptable according to the properties (affinity, activity, stability and/or specificity) to improve.
